T Acute Lymphoblastic Leukemia - CD7-targeted CAR-T immunotherapy - TP53 mutation

Association details:

Biomarker:	TP53 mutation
Cancer:	T Acute Lymphoblastic Leukemia
Drug Class:	CD7-targeted CAR-T immunotherapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C4 – Case Studies

Source:

ASH 2021

Title:

Haplo-Identical Non-Gene Editing CD7 CAR T-Cells Induced Bone Marrow and Extramedullary Remission in a Pediatric Patient with TP53 Mutated Relapsed and Refractory Early T-Cell Precursor Lymphoblastic Leukemia/Lymphoma after Haploidentical Hematopoietic Stem Cell Transplantation

Published date:

11/04/2021

Excerpt:

Here, we presented the efficacy and safety results of CD7-CART therapy in a pediatric patient with TP53 mutated ETP-ALL/LBL….A total of 5×10 6/kg CD7-CART-cells were infused. CR was confirmed at day 30 bone marrow evaluation and maintained at the last followup at day 91. Partial remission was achieved as evaluated by PET-CT scan at day 93.

DOI:

https://doi.org/10.1182/blood-2021-151587